CSIMarket
 


Igm Biosciences Inc   (IGMS)
Other Ticker:  
 

Igm Biosciences Inc 's Quick Ratio

IGMS's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Igm Biosciences Inc 's Cash & cash equivalent grew by 0.03 % in the III Quarter 2023 sequentially, while Current Liabilities decreased, this led to improvement in Igm Biosciences Inc 's Quick Ratio to 9.01, Quick Ratio remained below Igm Biosciences Inc average.

Within Major Pharmaceutical Preparations industry 107 other companies have achieved higher Quick Ratio than Igm Biosciences Inc in third quarter 2023. While Quick Ratio total ranking in the third quarter 2023 has deteriorated compared to the prior quarter from 120 to 334.

Explain Quick Ratio?
How much Cash & cash equivalents IGMS´s has?
What are IGMS´s Current Liabilities?


IGMS Quick Ratio (Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
(Sep 30 2022)
III. Quarter
Y / Y Current Liabilities Change -3.41 % 23.68 % 59.43 % 60.85 % 117.52 %
Y / Y Cash & cash equivalent Change -17.51 % -24.62 % 99.18 % 86.09 % 80.78 %
Quick Ratio MRQ 9.01 8.73 8.56 9.56 10.55
IGMS's Total Ranking # 334 # 120 # 358 # 371 # 387
Seq. Current Liabilities Change -3.01 % 1.53 % -2.36 % 0.45 % 24.2 %
Seq. Cash & cash equivalent Change 0.03 % 3.61 % -12.59 % -8.95 % -8.59 %



Quick Ratio third quarter 2023 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 108
Healthcare Sector # 183
Overall Market # 334


Quick Ratio Statistics
High Average Low
37.68 15.8 6.85
(Sep 30 2019)   (Mar 31 2022)




Financial Statements
Igm Biosciences Inc 's Current Liabilities $ 43 Millions Visit IGMS's Balance sheet
Igm Biosciences Inc 's Cash & cash equivalent $ 387 Millions Visit IGMS's Balance sheet
Source of IGMS's Sales Visit IGMS's Sales by Geography


Cumulative Igm Biosciences Inc 's Quick Ratio

IGMS's Quick Ratio for the trailling 12 Months

IGMS Quick Ratio

(Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
(Sep 30 2022)
III. Quarter
Y / Y Current Liabilities TTM Growth -3.41 % 23.68 % 59.43 % 60.85 % 117.52 %
Y / Y Cash & cash equivalent TTM Growth -17.51 % -24.62 % 99.18 % 86.09 % 80.78 %
Quick Ratio TTM 8.97 9.35 10.57 10.48 10.33
Total Ranking TTM # 3146 # 3263 # 2718 # 3717 # 3162
Seq. Current Liabilities TTM Growth -3.01 % 1.53 % -2.36 % 0.45 % 24.2 %
Seq. Cash & cash equivalent TTM Growth 0.03 % 3.61 % -12.59 % -8.95 % -8.59 %


On the trailing twelve months basis In spite of the year on year decrease in IGMS's Current Liabilities to $42.97 millions, cumulative Quick Ratio to 8.97 below the IGMS average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 463 other companies have achieved higher Quick Ratio than Igm Biosciences Inc . While Quick Ratio overall ranking has improved so far to 3146, from total ranking during the twelve months ending second quarter 2023 at 3263.

Explain Quick Ratio?
How much Cash & cash equivalents IGMS´s has?
What are IGMS´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 464
Healthcare Sector # 944
Within the Market # 3146


trailing twelve months Quick Ratio Statistics
High Average Low
25.62 12.99 2.52
(Jun 30 2020)   (Sep 30 2019)




Companies with similar Quick Ratio in the quarter ending Sep 30 2023, within Major Pharmaceutical Preparations Industry Quick RatioSep 30 2023 MRQ Cash & cash equivalentSep 30 2023 MRQ Current Liabilities
Belite Bio Inc  24.27 $ 88.157  Millions$ 3.633  Millions
Janux Therapeutics Inc   24.17 $ 349.712  Millions$ 14.471  Millions
Bright Minds Biosciences Inc   24.16 $ 5.197  Millions$ 0.215  Millions
Design Therapeutics Inc   23.48 $ 290.940  Millions$ 12.390  Millions
Lixte Biotechnology Holdings Inc   23.08 $ 5.106  Millions$ 0.221  Millions
Diamedica Therapeutics Inc   22.23 $ 46.465  Millions$ 2.090  Millions
Terns Pharmaceuticals Inc   22.06 $ 266.600  Millions$ 12.087  Millions
Cyteir Therapeutics Inc   21.65 $ 129.242  Millions$ 5.969  Millions
Ars Pharmaceuticals Inc   21.64 $ 241.902  Millions$ 11.180  Millions
Xenon Pharmaceuticals Inc   21.28 $ 526.674  Millions$ 24.744  Millions
Tyra Biosciences Inc   21.25 $ 215.652  Millions$ 10.147  Millions
Astria Therapeutics inc   21.23 $ 188.806  Millions$ 8.894  Millions
Sagimet Biosciences inc   20.59 $ 101.842  Millions$ 4.946  Millions
Eledon Pharmaceuticals Inc   20.56 $ 59.609  Millions$ 2.899  Millions
Acelyrin Inc   20.41 $ 381.738  Millions$ 18.702  Millions
Akero Therapeutics Inc   19.50 $ 554.732  Millions$ 28.447  Millions
Acasti Pharma Inc   19.33 $ 27.006  Millions$ 1.397  Millions
Pliant Therapeutics Inc   19.11 $ 523.612  Millions$ 27.395  Millions
Eqrx Inc   19.03 $ 1,212.933  Millions$ 63.726  Millions
Pmv Pharmaceuticals Inc   18.84 $ 201.918  Millions$ 10.716  Millions
Ideaya Biosciences Inc   18.83 $ 468.751  Millions$ 24.893  Millions
Savara Inc   18.77 $ 168.251  Millions$ 8.963  Millions
Medicinova Inc   18.38 $ 51.507  Millions$ 2.802  Millions
Immuneering Corporation  18.28 $ 97.243  Millions$ 5.321  Millions
Fulcrum Therapeutics Inc   18.27 $ 257.091  Millions$ 14.075  Millions
Stoke Therapeutics Inc   18.18 $ 214.718  Millions$ 11.811  Millions
Edgewise Therapeutics inc   17.73 $ 289.697  Millions$ 16.338  Millions
Kura Oncology Inc   17.51 $ 452.593  Millions$ 25.843  Millions
Olema Pharmaceuticals inc   17.34 $ 276.901  Millions$ 15.966  Millions
Keros Therapeutics Inc   17.24 $ 287.893  Millions$ 16.701  Millions

Date modified: 2023-11-14T22:12:05+00:00



Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com